Healx, a pioneer in AI-powered drug discovery for rare and neglected conditions, has partnered with SCI Ventures - the world’s first specialist venture fund focused on curing paralysis- to accelerate ...

XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the ...

AI has been a buzzword in the pharmaceutical industry for almost a decade, with countless headlines promising to ...

Drug discovery has traditionally been slow, expensive and prone to failure, but AI and machine learning are set to change all ...

A deal between Shenzhen-based XTalPi and US firm DoveTree shows Chinese biotech AI capabilities are gaining recognition.

Symbiotic.blue, a biotech looking to build an AI-driven drug discovery platform, has begun a pre-seed funding round.

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...

Despite longstanding reliance on sputum smear microscopy, culture methods, and chest X-rays, conventional TB diagnostics ...

Given the variability between labs and the unique nature of R&D work, custom, niche AI tools are going to become much more ...

Academics from Oxford and Cambridge Universities and seasoned life sciences entrepreneurs have launched Symbiotic.blue, a new ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...